Evaluating bioequivalence of an injectable for Type-2 diabetes and weight management
Learn how Syngene supported a global pharma company in conducting human pharmacological studies for Semglutide as an injectable while overcoming clinical and analytical challenges.
Xenografted tumors share comparable fraction unbound and can be surrogated by mouse lung tissue
Publication: Drug Metabolism and Disposition
SynSight: Syngene’s data consortium
Syngene’s data consortium comprises a group of consenting clients working towards greater learning through predictive modeling to enable faster drug discovery.
Ensuring high-quality iPSCs to maximize drug discovery success
Learn the rigorous measures established at Syngene for tissue procurement, iPSC reprogramming, systematic cell banking, inventory management, and quality control of every iPSC batch to maximize drug discovery success.
The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, activecontrolled, double-blind trial
Publication: The Lancet
Comparing population level humoral and cellular immunity to SARS Cov 2 in Bangalore- India
Publication: Scientific Reports
Syngene’s Center of Excellence for Oligonucleotides: Early Discovery to cGMP manufacturing services
Our Oligonucleotides facility offers end-to-end services, from early discovery to cGMP manufacturing. Specialty areas include chemically synthesized high-quality modified and non-modified custom oligonucleotide (DNA/RNA); siRNA (single & double-stranded); miRNA (modified and non-modified); antisense oligonucleotides; phosphodiesters and morpholinos; all types of oligo conjugates, and all types of base and custom modifications.
Syngene’s Small Molecule cGMP commercial manufacturing facility
Syngene’s state-of-the-art small molecule cGMP manufacturing facility is USFDA and PMDA-approved. The facility manufactures clinical (early and late-phase) and commercial drug substances (NCEs), advanced intermediates, regulatory starting materials, and selected generic APIs for clients. The facility’s manufacturing output ranges from grams to hundreds of kilograms per batch, with total volumes ranging from 60L to 8000L.
Syngene’s high potent API manufacturing facility
Our high potent API facility is designed to handle cytotoxic and cytostatic high-potency compounds with a commitment to safety.
How Syngene supported a large pharma company in generating gene knockouts in iPSCs with >95% efficiency
Learn how Syngene helped generate human iPSCs gene knockouts with >95% efficiency for an allogeneic cell and gene therapy.
